Introduction: Biological drugs are currently used for the treatment of chronic inflammatory, autoimmune, and neoplastic diseases. With their expanding indication spectrum and increasing use, hypersensitivity reactions to these drugs are also becoming more frequent. The present study aimed to report the incidence and the features of such reactions in pediatric patients using biologicals for the treatment of various diseases. Methods: The medical records of pediatric patients treated with biological agents between October 1, 2011 and August 31, 2019 were reviewed and adverse reactions were evaluated retrospectively. Results: During the study period, 211 patients (116 boys, 55%) used 21 different biological drugs for the treatment of various diseases. Their median age at the time of the first treatment was 139.9 (IQR: 92.2–187.8) months. Hematologic-oncologic diseases were the most common indication for biological therapy (97/211; 46.0%), followed by rheumatologic diseases (82/211; 38.9%). Of the 211 patients, 14 (6.64%) experienced reactions to biological drugs. The most common culprit agent was rituximab (57.1%). Most of the patients (85.7%) had a history of reactions either during the infusion or within 1 h after taking the drug. Five patients underwent desensitization to the culprit drug, while 7 other patients continued treatment with a reduced dose/infusion rate or premedication. Also 1 patient continued to take the drug without any additional treatment. Conclusion: It was reported that 6.64% of the patients who received biologic drug therapy for various reasons in our hospital had hypersensitivity. The most common culprit agent was rituximab, and most of the reactions were immediate reactions.
Int Arch Allergy Immunol

中文翻译：

---

儿科患者使用生物药物的超敏反应评估

简介：生物药物目前用于治疗慢性炎症、自身免疫和肿瘤疾病。随着适应症范围的扩大和使用的增加，对这些药物的超敏反应也变得更加频繁。本研究旨在报告使用生物制剂治疗各种疾病的儿科患者中此类反应的发生率和特征。方法：回顾性分析2011年10月1日至2019年8月31日期间接受生物制剂治疗的儿科患者病历，并回顾性评价不良反应。结果：研究期间，211名患者（116名男孩，55%）使用了21种不同的生物药物治疗各种疾病。他们在第一次治疗时的中位年龄为 139.9 (IQR: 92.2–187.8) 个月。血液肿瘤疾病是生物治疗最常见的适应症（97/211；46.0%），其次是风湿病（82/211；38.9%）。在 211 名患者中，14 名 (6.64%) 出现了对生物药物的反应。最常见的罪魁祸首是利妥昔单抗 (57.1%)。大多数患者（85.7%）在输注期间或服药后1小时内有反应史。5 名患者接受了对罪犯药物的脱敏治疗，而另外 7 名患者继续以降低的剂量/输注速度或术前用药进行治疗。还有 1 名患者在没有任何额外治疗的情况下继续服用该药物。结论：据报道，我院因各种原因接受生物药物治疗的患者中有6.64%存在过敏反应。最常见的罪魁祸首是利妥昔单抗，大多数反应是即刻反应。
Int Arch 过敏免疫